Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study

BMC Ophthalmology

Volumn 8, Issue , 2008, Pages

  Paolera, Mauricio D ^a   Kasahara, Niro ^a   Umbelino, Cristiano C ^a   Walt, John G ^a  

^a Allergan Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; EYE DROPS; LATANOPROST; PRESERVATIVE; AMIDE; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE; PROSTAGLANDIN F;

ARTICLE; BRAZIL; DRUG DEGRADATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; OPEN STUDY; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STORAGE TEMPERATURE; ADULT; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG PACKAGING; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEASON; STANDARD; TEMPERATURE; TIME;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DRUG PACKAGING; DRUG STABILITY; FOLLOW-UP STUDIES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; SEASONS; TEMPERATURE; TIME FACTORS;

EID: 46149104367     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-8-11     Document Type: Article

References (27)

1. Effects of common ophthalmic preservatives on ocular health. R Noecker, Adv Ther 2001 18 205 215 10.1007/BF02853166 11783457
2. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. S Gandolfi ST Simmons R Sturm K Chen AM VanDenburgh the Bimatoprost Study Group 3, Adv Ther 2001 18 110 121 10.1007/BF02850299 11571823
3. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. RJ Noecker MS Dirks NT Choplin P Bernstein AL Batoosingh SM Whitcup the Bimatoprost/Latanoprost Study Group, Am J Ophthalmol 2003 135 55 63 10.1016/S0002-9394(02)01827-5 12504698
4. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. M Sherwood J Brandt the Bimatoprost Study Groups 1 and 2, Surv Ophthalmol 2001 145 Suppl 4 S361 S368 10.1016/S0039-6257(01)00219-3
5. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. A Alm I Widengård D Kjellgren M Söderström B Friström A Heijl J Stjerschantz, Br J Ophthalmol 1995 79 12 21 7880782 10.1136/bjo.79.1.12
6. Phase III latanoprost studies in Scandinavia, the United Kingdom, and the United States. A Alm CB Camras PG Watson, Surv Ophthalmol 1997 41 Suppl 2 S105 S110 9154285
7. ® (latanoprost ophthalmic solution) 0.005%. Package insert. 2006
8. Effect of temperature and light on the stability of latanoprost and its clinical relevance. PV Morgan S Proniuk J Blanchard RJ Noecker, J Glaucoma 2001 10 401 405 10.1097/00061198-200110000-00007 11711838
9. World Map of Köppen-Geiger Climate Classification updated. M Kottek J Grieser C Beck B Rudolf F Rubel, Meteorol Z 2006 15 259 263 http://koeppen-geiger.vu-wien.ac.at Accessed May 30, 2007 10.1127/0941-2948/ 2006/0130
10. Concentration of latanoprost ophthalmic solution after 4 to 6 weeks' use in an eye clinic setting. R Varma J Winarko T Kiat-Winarko B Winarko, Invest Ophthalmol Vis Sci 2006 47 222 225 10.1167/iovs.04-1367 16384966
11. Stability of latanoprost in an ophthalmic lipid emulsion using polyvinyl alcohol. Y Sakai S-I Yasueda A Ohtori, Int J Pharmaceutics 2005 305 176 179 10.1016/j.ijpharm.2005.08.017
12. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. GD Novack R Evans, J Glaucoma 2001 10 483 486 10.1097/00061198-200112000-00008 11740219
13. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. H DuBiner D Cooke M Dirks WC Stewart AM VanDenburgh C Felix, Surv Ophthalmol 2001 45 Suppl 4 S353 60 10.1016/S0039-6257(01)00212-0 11434938
14. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. S Gandolfi ST Simmons R Sturm K Chen AM VanDenburgh Bimatoprost Study Group 3, Adv Ther 2001 18 110 21 10.1007/BF02850299 11571823
15. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. TR Walters HB DuBiner SP Carpenter B Khan AM VanDenburgh Bimatoprost Circadian IOP Study Group, Surv Ophthalmol 2004 49 Suppl 1 S26 35 10.1016/j.survophthal.2003. 12.017 15016559
16. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. MS Dirks RJ Noecker M Earl S Roh SM Silverstein RD Williams, Adv Ther 2006 23 385 94 10.1007/BF02850159 16912020
17. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. RK Parrish P Palmberg WP Sheu XLT Study Group, Am J Ophthalmol 2003 135 688 703 10.1016/S0002-9394(03)00098-9 12719078
18. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. ST Simmons MS Dirks RJ Noecker, Adv Ther 2004 21 247 62 10.1007/BF02850157 15605619
19. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. P Denis A Lafuma B Khoshnood V Mimaud G Berdeaux, Curr Med Res Opin 2007 23 601 8 10.1185/030079907X178720 17355741
20. Intraocular pressure fluctuation is a risk factor for glaucomatous visual field progression in AGIS. K Nouri-Mahdavi D Hoffman DE Gaasterland J Capriolo, Presented at the Annual Meeting of the American Academy of Ophthalmology 2003
21. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. S Asrani R Zeimer J Wilensky D Gieser S Vitale K Lindenmuth, J Glaucoma 2000 9 134 142 10782622
22. A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension. B Friström SEG Nilsson, Br J Ophthalmol 1997 81 867 870 9486028
23. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients: a randomized, double masked comparison with timolol 0.5%. M Diestelhorst S Roters GK Krieglstein, Graefes Arch Clin Exp Ophthalmol 1997 235 20 6 10.1007/BF01007833 9034838
24. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). DF Woodward AH Krauss J Chen Y Liang C Li CE Protzman A Bogardus R Chen KM Kedzie HA Krauss DW Gil A Kharlamb LA Wheeler D Babusis D Welty DD Tang-Liu M Cherukury SW Andrews RM Burk ME Garst, J Pharmacol Exp Ther 2003 305 772 785 10.1124/jpet.102.047837 12606640
25. Comparison of the ocular hypotensive lipid AGN 192024 with timolol. RA Laibovitz AM VanDenburgh C Felix R David A Batoosingh A Rosenthal J Cheetham, Arch Ophthalmol 2001 119 994 1000 11448321
26. ® (bimatoprost ophthalmic solution) 0.03%. Package insert. 2006
27. Efficiency of instillation methods for prostaglandin medications. R Fiscella JT Wilensky TH Chiang JG Walt, J Ocul Pharmacol Ther 2006 22 477 482 10.1089/jop.2006.22.477 17238816